These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34101154)

  • 1. Measurement of changes in endogenous serotonin level by positron emission tomography with [
    Ikoma Y; Takuwa H; Nishino A; Maeda J; Kawamura K; Obata T; Zhang MR; Higuchi M; Suhara T
    Ann Nucl Med; 2021 Aug; 35(8):955-965. PubMed ID: 34101154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [¹⁸F]Altanserin and small animal PET: impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT₂A receptor densities in the rat brain.
    Kroll T; Elmenhorst D; Matusch A; Celik AA; Wedekind F; Weisshaupt A; Beer S; Bauer A
    Nucl Med Biol; 2014 Jan; 41(1):1-9. PubMed ID: 24120220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct comparison of [(18) F]MH.MZ and [(18) F] altanserin for 5-HT2A receptor imaging with PET.
    Hansen HD; Ettrup A; Herth MM; Dyssegaard A; Ratner C; Gillings N; Knudsen GM
    Synapse; 2013 Jun; 67(6):328-37. PubMed ID: 23390031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain.
    Smith GS; Price JC; Lopresti BJ; Huang Y; Simpson N; Holt D; Mason NS; Meltzer CC; Sweet RA; Nichols T; Sashin D; Mathis CA
    Synapse; 1998 Dec; 30(4):380-92. PubMed ID: 9826230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin 2A receptor agonist binding in the human brain with [(11)C]Cimbi-36: Test-retest reproducibility and head-to-head comparison with the antagonist [(18)F]altanserin.
    Ettrup A; Svarer C; McMahon B; da Cunha-Bang S; Lehel S; Møller K; Dyssegaard A; Ganz M; Beliveau V; Jørgensen LM; Gillings N; Knudsen GM
    Neuroimage; 2016 Apr; 130():167-174. PubMed ID: 26876490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognition-induced modulation of serotonin in the orbitofrontal cortex: a controlled cross-over PET study of a delayed match-to-sample task using the 5-HT2a receptor antagonist [18F]altanserin.
    Hautzel H; Müller HW; Herzog H; Grandt R
    Neuroimage; 2011 Oct; 58(3):905-11. PubMed ID: 21722741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging.
    Rosier A; Dupont P; Peuskens J; Bormans G; Vandenberghe R; Maes M; de Groot T; Schiepers C; Verbruggen A; Mortelmans L
    Psychiatry Res; 1996 Nov; 68(1):11-22. PubMed ID: 9027929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography.
    Quednow BB; Treyer V; Hasler F; Dörig N; Wyss MT; Burger C; Rentsch KM; Westera G; Schubiger PA; Buck A; Vollenweider FX
    Neuroimage; 2012 Feb; 59(4):3922-32. PubMed ID: 21996132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907.
    Kristiansen H; Elfving B; Plenge P; Pinborg LH; Gillings N; Knudsen GM
    Synapse; 2005 Dec; 58(4):249-57. PubMed ID: 16206185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge.
    Pinborg LH; Adams KH; Yndgaard S; Hasselbalch SG; Holm S; Kristiansen H; Paulson OB; Knudsen GM
    J Cereb Blood Flow Metab; 2004 Sep; 24(9):1037-45. PubMed ID: 15356424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach.
    Haugbøl S; Pinborg LH; Arfan HM; Frøkjaer VM; Madsen J; Dyrby TB; Svarer C; Knudsen GM
    Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):910-5. PubMed ID: 17195073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans.
    Matusch A; Hurlemann R; Rota Kops E; Winz OH; Elmenhorst D; Herzog H; Zilles K; Bauer A
    J Neural Transm (Vienna); 2007; 114(11):1433-42. PubMed ID: 17541696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls.
    Sadzot B; Lemaire C; Maquet P; Salmon E; Plenevaux A; Degueldre C; Hermanne JP; Guillaume M; Cantineau R; Comar D
    J Cereb Blood Flow Metab; 1995 Sep; 15(5):787-97. PubMed ID: 7673371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suitability of [18F]altanserin and PET to determine 5-HT2A receptor availability in the rat brain: in vivo and in vitro validation of invasive and non-invasive kinetic models.
    Kroll T; Elmenhorst D; Matusch A; Wedekind F; Weisshaupt A; Beer S; Bauer A
    Mol Imaging Biol; 2013 Aug; 15(4):456-67. PubMed ID: 23456885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A PET [18F]altanserin study of 5-HT2A receptor binding in the human brain and responses to painful heat stimulation.
    Kupers R; Frokjaer VG; Naert A; Christensen R; Budtz-Joergensen E; Kehlet H; Knudsen GM
    Neuroimage; 2009 Feb; 44(3):1001-7. PubMed ID: 19007894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans.
    Price JC; Lopresti BJ; Meltzer CC; Smith GS; Mason NS; Huang Y; Holt DP; Gunn RN; Mathis CA
    Synapse; 2001 Jul; 41(1):11-21. PubMed ID: 11354009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic analysis of [
    Pauwelyn G; Vlerick L; Dockx R; Verhoeven J; Dobbeleir A; Bosmans T; Peremans K; Vanhove C; Polis I; De Vos F
    BMC Vet Res; 2019 Nov; 15(1):415. PubMed ID: 31752848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm.
    van Dyck CH; Soares JC; Tan PZ; Staley JK; Baldwin RM; Amici LA; Fu X; Garg PK; Seibyl JP; Charney DS; Innis RB
    Nucl Med Biol; 2000 Nov; 27(8):715-22. PubMed ID: 11150702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation and quantification of [18F]altanserin binding in the rat brain using blood input and reference tissue modeling.
    Riss PJ; Hong YT; Williamson D; Caprioli D; Sitnikov S; Ferrari V; Sawiak SJ; Baron JC; Dalley JW; Fryer TD; Aigbirhio FI
    J Cereb Blood Flow Metab; 2011 Dec; 31(12):2334-42. PubMed ID: 21750562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motion artifact reduction on parametric PET images of neuroreceptor binding.
    Herzog H; Tellmann L; Fulton R; Stangier I; Rota Kops E; Bente K; Boy C; Hurlemann R; Pietrzyk U
    J Nucl Med; 2005 Jun; 46(6):1059-65. PubMed ID: 15937320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.